Liu, Z., Le, K., Zhou, X., Alexander, J. L., Lin, S., Bewshea, C., …Powell, N. (2023). Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study. The Lancet Gastroenterology & Hepatology, 8(2), 145-156. https://doi.org/10.1016/S2468-1253%2822%2900389-2